Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...
Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Zacks Research Has Weak Estimate for DNLI FY2024 Earnings
Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...
Tracking Baillie Gifford's 13F Portfolio - Q4 2024 Update
Baillie Gifford's 13F portfolio shows changes in top holdings like Amazon and NVIDIA, with increased stakes in SEA Ltd. Read ...
Denali Therapeutics (NASDAQ:DNLI) Price Target Cut to $40.00 by Analysts at The Goldman Sachs Group
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...
Hosted on MSN13d
Biotech Market Forecast: Top Trends for Biotech in 2025
The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
Fidelity International20d
Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's ...
Yahoo Finance21d
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...